The University of Nebraska Medical Center is involved in a clinical trial of a drug that is on the fast track towards approval by the Food and Drug Administration. Dr. Julie Vose is the chief of hematology and oncology and a professor at UNMC and says it holds great potential for those suffering with mantle cell lymphoma and other cancers.
The experimental drug, Ibruitinib is being offered to patients through an expanded access program which occurs about six months before the drug is approved by the FDA. Dr. Vose says patients who have been on the treatment have had remarkable results with limited side effects. This study will target those ages 18 and older with mantle cell lymphoma who have relapsed and other treatments have failed.
UNMC reports the drug works differently than other drugs for this type of cancer by poisoning one of the pathways that helps the cancer grow. Dr. Vose says the drug has limited side effects and is in a pill form rather than intravenous.
UNMC is one of about 50 locations across the U-S and in Puerto Rico taking part in the clinical trial.